Compare D&B Risk Analytics vs. iRISK

Globally, teams in risk, procurement, and compliance are under pressure to manage geopolitical risks and business risks. Third-party risks are impacted by the complexity of domestic and international businesses, as well as complex and diverse regulations. It is crucial that companies proactively manage third-party relationships. This cutting-edge platform, powered by D&B Data Cloud's 520M+ Global Business Records with 2B+ annual updates for third-party risks, is an AI-powered solution that mitigates and monitors counterparty risk on a continual basis. D&B Risk Analytics uses best-in class risk data, including alerts for high-risk purchases and match points of more than a billion. This helps to drive informed decisions. Intelligent workflows allow for quick and thorough screening. Receive alerts on key business indicators.

Uncover a comprehensive solution that consolidates all facets of risk management, enabling you to recognize, assess, and prioritize risks within a single, robust platform. This powerful tool not only enhances your operational processes and decision-making but also elevates your organization's overall performance. ValGenesis iRisk serves as an advanced risk management solution tailored for the life sciences sector, founded on industry-leading practices and developed by subject matter experts with hands-on experience. Embark on a transformative journey to effectively grasp and handle risks throughout the lifecycle of your products. iRISK™ stands as a cutting-edge Risk Management Platform specifically designed for the pharmaceutical sector, crafted in accordance with the best practices of the industry and shaped by insights from its experts, to create scientifically-based risk strategies for various products, processes, and components in a structured and compliant manner. By integrating risk management and knowledge management functionalities into one cohesive platform, iRISK™ empowers organizations to streamline their workflows and enhance efficiency across all stages of product development and deployment. Ultimately, this holistic approach to risk management fosters a culture of continuous improvement and innovation in the life sciences industry.